RxDoctor Payments DataLook up a doctor →

Brigitte Lovell, DMD

Orofacial Pain · Ojai, CANPI 1033349170

Payments from drug & device makers

$289,972in general payments, 2019–2025

Across 682 payments — averaging $425.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$197K
  • Amgen$28K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Teva Pharmaceuticals USA, Inc.$13K
  • Impel Pharmaceuticals Inc.$12K
  • Lilly USA, LLC$8K
  • plus $18K from 21 others

What the payments were for

  • Consulting fees$15,3655%
  • Speaking & faculty fees$226,09078%
  • Travel & lodging$30,12710%
  • Food & beverage$18,3196%
  • Education$710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few orofacial pain providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$156,540
Medicare patients
192
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe42$46,307
Nurtec OdtRimegepant Sulfate22$37,244
UbrelvyUbrogepant18$26,263
Emgality PenGalcanezumab-Gnlm35$24,092
ImitrexSumatriptan Succinate19$13,389
Ajovy SyringeFremanezumab-Vfrm12$8,557
Sumatriptan Succinate60$7,356
Frovatriptan Succinate12$6,315
Sumatriptan20$5,035
RizatriptanRizatriptan Benzoate32$1,396
Carbamazepine ErCarbamazepine13$1,054
Gabapentin41$619
Memantine Hcl18$589
Naratriptan Hcl17$414
Ondansetron OdtOndansetron18$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$5,220$37,24422 claims
AbbVieUbrelvy$197,322$26,26318 claims
Upsher-smith Laboratories LLCTopiramate$169$30422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few orofacial pain providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other orofacial pain in Ojai

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →